Tony Lubiniecki

Quality by Design for Biotechnology Products

A. Rathore, R. Greene, J. Mercer, 2009 .

Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.

Tony Lubiniecki, M. Rossi, P. Garidel, 2015, Biologicals : journal of the International Association of Biological Standardization.

Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy.

Tony Lubiniecki, M. Rossi, P. Garidel, 2015, Journal of pharmaceutical sciences.